BioSpace News Archive

Adiso Therapeutics, Inc. announced that it has completed enrollment of its first cohort of patients in a Phase 1b clinical study evaluating ADS051, an oral, gut-restricted, small molecule modulator of neutrophil trafficking and activation, as a potential treatment for patients with moderately-to-severely active ulcerative colitis.

ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today provided an update on its sepofarsen program, following a comprehensive post-hoc analysis of the data from the Phase 2/3 Illuminate trial in people with CEP290-mediated Leber congenital amaurosis 10, or LCA10, a severe inherited retinal disease.

Axogen, Inc. today announced that it will report first quarter 2022 financial results on Wednesday, May 4, 2022 after the market closes.

VantAI, an AI-first induced-proximity company, today announced it has entered into a multi-year collaboration agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (‘Janssen’).

Glaukos Corporation plans to release first quarter 2022 financial results after the market close on Wednesday, May 4, 2022.

LENZ Therapeutics today announced that it has entered into an exclusive license agreement with Ji Xing Pharmaceuticals (JIXING) to develop and commercialize LNZ100 (aceclidine) and LNZ101 (aceclidine + brimonidine) for the treatment of presbyopia in Greater China.

iSpecimen Inc. today announced that it added Acutis Diagnostics (“Acutis”), a clinical diagnostics laboratory, to its platform as a laboratory services provider.

9 Meters Biopharma, Inc. announced today that the Company has received notice from the United States Patent and Trademark Office (USPTO) that U.S. Patent Application No. 16/781,304 is allowed.

Praxis Precision Medicines, Inc. announced that the Company will host an Epilepsy Day from 8:30 a.m. to 11:30 a.m. ET on Wednesday, April 27, 2022 virtually and in New York City.

aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for its lead therapeutic candidate, efzofitimod, for the treatment of systemic sclerosis (SSc, also known as scleroderma).